PHARMACOKINETIC STUDIES OF NEW SILVER-BASED COMPLEX
Keywords:Silver-based complex, Pharmacokinetics, Antiviral drug, Silver distribution in tissues, Mass spectrometry, Argosil
Objective: Investigation of pharmacokinetics parameters of the new silver-based compound of general formula C6H19Ag2N4LiO6S2, called Argosilâ€, with high antiviral activity.
Methods: Water solution of complex administered intragastrically in the dose rate of 100 mg/kg body weight of mice BALB/c (males) aged 1.5-2.0 mo. Blood and tissues samples analyzed by mass spectrometry.
Results: Half-life of the drug was about 4 h at the initial stage. About 5% of the initially introduced silver detected after 24 h. Maximum drug concentration observed in the lung tissues.
Conclusion: Results make the basis for further test and clinical implementation. Taken into account low toxicity and antiviral properties of this compound, it looks especially effective for lung infections treatment.
Lansdown AB. Pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharm Sci 2010;2010:1-16.
Bachler G, von Goetz N, HungerbÃ¼hler K. A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles. Int J Nanomedicine 2013;8:3365-82.
Tikhonov VL, Donchenko AS, Glotovo TI, Silnikov VN, Tretyakov VV. Toxicity and antiviral activity of the new drug on the basis of silver Argobiotsin-2S. Siberian herald agricultural science (Rus) 2007;12:55-60.
Agilent 7500 ICP-MS Chemstation operation G3270-90111. Tokyo: Yokagawa Analitical Systems Inc; 2004:74.
Solovyev VN, Firsov AA, Filobbb v VA. Pharmacokinetics. Moscow: Medicine; 1980. p. 424.
Khabriev RW. Manual on experimental (preclinical) study of new pharmacological substances. Moscow: Medicine; 2005. p. 832.